Novinky v léčbě dyslipoproteinemie
| Title in English | What's new in the treatment of dyslipoproteinemia |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Proceedings |
| Conference | Aktuality z vnitřního lékařství 2016 : XXIII. kongres České internistické společnosti ČLS J.E. Purkyně, 21.-24.9.2016 |
| MU Faculty or unit | |
| Citation | |
| Field | Other specializations of internal medicine |
| Keywords | dyslipidemia; statins; ezetimibe; fenofibrate; PCSK9 inhibitors |
| Description | The first-line class of drugs for the treatment of dyslipidemia continue to be statins, Ezetimibe is a drug used primarily in combination with statins, and a recent interventions! study reported that ezetimibe also reduces the risk of coronary events. A combination of a statin with feaofibrate can be considered when treating individuals with combined dyslipidemia; however, there is only little evidence for this combination regarding its effect on cardiovascular events. A new class of lipid-lowering drugs, which should become available in the Czech Republic within several months, are PCSK9 inhibitors. |